Advisory Committees

Internal Advisory Committee (IAC)

IAC is charged with monitoring the progress of the RPIs, and advising the PI on COBRE development. Many committee members are past or current COBRE PIs. The duties of the Internal Advisory Committee include:

• Meet with RPls, review their progress reports, and provide comments for the RPIs' projects every quarter.
• Review all grant proposals from the RPIs and provide feedback for the grant proposals.
• Monitor all Core services to ensure the effectiveness of the Core operations.
• Follow the academic growth of RPIs and set the milestones for RPIs.
• Nominate and select new RPI candidates and search for new candidates to recruit to OU Health Sciences Center.
• Advise the PI in the selection of new RPI candidates and the search for new candidates to recruit to OU Health Sciences Center.
• Advise the PI concerning the COBRE operation and policy.

Members

Judith James, MD, PhD
GLC Research Professor of Medicine
Associate Vice Provost for Clinical & Translational Science
Director, Oklahoma Clinical & Translational Science Institute
OMRF Vice President of Clinical Affairs
Member and Program Chair Arthritis and Clinical Immunology Research

Rodger P. McEver, M.D.
OMRF Vice President of Research
Adjunct Professor, Department of Biochemistry and Molecular Biology
University of Oklahoma Health Sciences

Darrin R. Akins, PhD
Professor
Vice President for Research

External Advisory Committee

An External Advisory Committee, consisting of five nationally recognized cancer scientists, will meet with the PI, the Internal Advisory Committee, and the RPIs twice a year, monitoring the progress of their projects as well as the overall progress of the COBRE. These researchers will meet with the COBRE investigators twice per year: once in the fall in Oklahoma and once in the spring during the annual meeting of the American Association for Cancer Research.

The proposed External Advisory Committee of the COBRE will have the following responsibilities:

• Critique the scientific progress of the COBRE, including the investigator projects and the core modules.
• Interact one-on-one with RPIs and provide guidance and recommendations.
• Monitor and critique the COBRE policy and operation, including selecting RPI and milestones for progress.
• Monitor the Core services and utilization.
• Review applications and assist in the selection of new investigators who request funding in subsequent years. The selections will then be forwarded by the PI to NIH for further review and approval.
• Provide advice and direction to the PI and IAC regarding all aspects of the program.
• Critique the performance of the PI.
• The EAC will prepare a written report at the fall meeting. Minutes will be recorded at the spring meeting. Both will be available for review by NIH program staff.

Members

Channing J. Der, PhD
Professor, Department of Pharmacology Director, NIH Cancer Cell Biology Training
Lineberger Comprehensive Cancer Center
University of North Carolina, Chapel Hill, NC

J. Silvio Gutkind, PhD
Chief, Oral and Pharyngeal Cancer Branch
NIDCR
National Institutes of Health

Jennifer Grandis, MD
Program Leader, Head & Neck Cancer Program
University of Pittsburgh Cancer Institute

Premkumar Reddy, PhD
Professor and Director Experimental Therapeutics Institute
Mount Sinai School of Medicine, NY